EUVIMEDEUVIMED entdecken
Crossref

Primary hypothyroidism after treatment for childhood cancer in the Dutch Childhood Cancer Survivor Study: Hypothyroidism in childhood cancer survivors

S van der Leij iD, Jop C Teepen iD, Leontien C M Kremer, Heleen J H van der Pal, M M van den Heuvel-Eibrink, Dorine Bresters, Andrica C H de Vries, A J Keijzer-Schellekens, Cecile M Ronckers, Rosella Hermens, Marloes Louwerens, Sebastian Neggers und 2 weitere

Cancer · 15.12.2025 · 131 (24)

DOI: 10.1002/cncr.70198 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, online erschienen am 10.12.2025. Verfasst von S van der Leij und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, University Medical Center, Utrecht, the Netherlands. Hauptthemen laut MEDLINE: Hypothyroidism, Cancer Survivors, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Stichting Kinderen Kankervrij, KWF Kankerbestrijding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Primary hypothyroidism is common in childhood cancer survivors (CCS). Exposure to radiation and hematopoietic stem cell transplantation (HSCT) are known risk factors; however, the impact of chemotherapy and the role of thyroid peroxidase antibodies (anti‐TPO) remain unclear. The prevalence of primary hypothyroidism, anti‐TPO, and treatment‐related risk factors in a cohort of CCS was assessed.

Methods

In total, 1774 five‐year CCS were included. The prevalence of primary hypothyroidism according to treatment strategy was evaluated: radiotherapy involving the thyroid gland (±chemotherapy), chemotherapy only, HSCT, and controls. Multivariable logistic regression was performed to identify risk factors for hypothyroidism.

Results

After a median follow‐up time of 25.3 years (range, 14.8–54.7), primary hypothyroidism was present in 8.2%. When evaluating subgroups specifically, the prevalence of primary hypothyroidism increased to 28% in CCS treated with radiotherapy and 30.6% after HSCT. In multivariable analyses, survivors treated with chemotherapy only were not at increased risk of hypothyroidism (odds ratio [OR], 0.74; 95% CI, 0.28–2.00), whereas survivors treated with radiotherapy had an almost 14‐fold increased risk (OR, 13.91; 95% CI, 5.34–36.22). In irradiated CCS, the use of platinating agents was associated with an increased risk of hypothyroidism (OR, 3.25; 95% CI, 1.39–7.59). The prevalence of anti‐TPO did not differ between the treatment groups ( p = .42).

Conclusions

Primary hypothyroidism is prevalent after radiation exposure and HSCT. Chemotherapy only does not increase the risk for primary hypothyroidism. The use of platinating agents combined with radiotherapy may increase its risk. Treatment for childhood cancer does not increase the risk of anti‐TPO.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypothyroidismCancer SurvivorsNeoplasmsHumansMaleFemaleChildAdolescentNetherlandsChild, PreschoolHematopoietic Stem Cell TransplantationRisk FactorsAdultPrevalenceYoung AdultInfantIodide PeroxidaseRadiotherapyAutoantibodiesFollow-Up Studies

Stichwörter der Autor:innen

childhood cancer survivorslate effectsprimary hypothyroidism

Substanzen

Iodide PeroxidaseAutoantibodies

Autor:innen und Institutionen

  • Department of Endocrinology, University Medical Center, Utrecht, the Netherlands.
  • Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
  • Division of Childhealth, Wilhelmina Children's Hospital, Utrecht, the Netherlands.
  • Department of Pediatric Oncology, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • Department of Childhood Cancer Epidemiology, University Medicine at Johannes Gutenberg, University Mainz, Mainz, Germany.
  • Department of Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.

ORCID-Profile: S van der Leij, Jop C Teepen

Förderung

  • Stichting Kinderen Kankervrij
  • KWF Kankerbestrijding

Zitieren

APA

van der Leij, S., Teepen, J. C., Kremer, L. C. M., van der Pal, H. J. H., van den Heuvel-Eibrink, M. M., Bresters, D., de Vries, A. C. H., Keijzer-Schellekens, A. J., Ronckers, C. M., Hermens, R., Louwerens, M., Neggers, S., Valk, G. D., & van Santen, H. M. (2025). Primary hypothyroidism after treatment for childhood cancer in the Dutch Childhood Cancer Survivor Study: Hypothyroidism in childhood cancer survivors. Cancer, 131(24). https://doi.org/10.1002/cncr.70198

Vancouver

van der Leij S, Teepen JC, Kremer LCM, van der Pal HJH, van den Heuvel-Eibrink MM, Bresters D, et al. Primary hypothyroidism after treatment for childhood cancer in the Dutch Childhood Cancer Survivor Study: Hypothyroidism in childhood cancer survivors. Cancer. 2025;131(24). doi:10.1002/cncr.70198

BibTeX
@article{vanderLeij2025,
  author = {van der Leij, S and Teepen, Jop C and Kremer, Leontien C M and van der Pal, Heleen J H and van den Heuvel-Eibrink, M M and Bresters, Dorine and de Vries, Andrica C H and Keijzer-Schellekens, A J and Ronckers, Cecile M and Hermens, Rosella and Louwerens, Marloes and Neggers, Sebastian and Valk, Gerlof D and van Santen, H M},
  title = {Primary hypothyroidism after treatment for childhood cancer in the Dutch Childhood Cancer Survivor Study: Hypothyroidism in childhood cancer survivors},
  journal = {Cancer},
  year = {2025},
  volume = {131},
  number = {24},
  doi = {10.1002/cncr.70198}
}
Kostenlos starten →